TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07444814: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Sponsor: Whitehawk Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 226 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07444814 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07444814 Rescue Dossier →